Search for: "Daubert v. Merrell Dow Pharmaceuticals, Inc." Results 101 - 120 of 218
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
16 Mar 2023, 4:30 am by Lawrence Solum
Merrell Dow Pharmaceuticals, Inc., (1993), on the standards for expert testimony, with 24 departing states, United States v. [read post]
19 Nov 2023, 2:31 pm by admin
Merrell Dow Pharmaceuticals, Inc.,[2] The Supreme Court suggested that peer review of studies relied upon by a challenged expert witness should be a factor in determining the admissibility of that expert witness’s opinion. [read post]
5 Apr 2010, 1:01 pm by Jeralyn
Dow Merrell Pharmaceuticals, Inc., which prohibit the use of inaccurate, nonspecific tests and/or conclusory reports because they do not prove the presence of marijuana in a seized substance. [read post]
29 Jan 2022, 6:24 pm by Jon L. Gelman
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579, 113 S.Ct. 2786, 125 L.Ed.2d 469 (1993), Fed.Rules, Evid.Rules 104(a), 702. [read post]
15 May 2014, 9:36 am by Matthew A. Reed
Breg Inc., 613 F.3d 1329, 1342 (11th Cir. 2010); see also Norris v. [read post]
17 Jan 2014, 8:27 pm by Alex Craigie
Merrell Dow Pharmaceuticals, Inc., the United States Supreme Court held for the first time that, to be admissible, scientific evidence must be both scientifically valid and properly applicable to the facts at issue in the case. [read post]
17 Mar 2014, 6:57 am by Bill Marler
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993). [read post]
22 Feb 2011, 7:27 pm by Gerald L. Maatman, Jr.
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), in analyzing the expert presentations relating to the Rule 23 requirements, Plaintiffs contend that the Ninth Circuit found this to be no abuse of discretion, and that it did not matter because the district court judge was "guided by Daubert," concluded that the expert opinions were "based on valid principles," and were "sufficiently probative" of the Rule 23… [read post]
22 Feb 2011, 7:27 pm by Gerald L. Maatman, Jr.
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), in analyzing the expert presentations relating to the Rule 23 requirements, Plaintiffs contend that the Ninth Circuit found this to be no abuse of discretion, and that it did not matter because the district court judge was "guided by Daubert," concluded that the expert opinions were "based on valid principles," and were "sufficiently probative" of the Rule 23 requirements. [read post]
4 Mar 2012, 9:02 am by Schachtman
Merrill Dow Pharmaceuticals, Inc., 874 F.2d 307, 311-12 (5th Cir. 1989)(“Fortunately, we do not have to resolve any of the above questions [as to bias and confounding], since the studies presented to us incorporate the possibility of these factors by the use of a confidence interval. [read post]
17 Jan 2014, 8:27 pm by Alex Craigie
Merrell Dow Pharmaceuticals, Inc., the United States Supreme Court held for the first time that, to be admissible, scientific evidence must be both scientifically valid and properly applicable to the facts at issue in the case. [read post]
27 Jul 2017, 2:00 am
MERRELL DOW PHARMACEUTICALS, INC 509 U.S. 579 (1993)KOKKONEN V. [read post]
31 Dec 2009, 2:34 am by Sean Wajert
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), and its federal and state progeny. [read post]
25 Apr 2015, 11:03 am by Schachtman
The first edition of the Reference Manual on Scientific Evidence [Manual] was published in 1994, a year after the Supreme Court delivered its opinion in Daubert. [read post]
6 Apr 2016, 12:06 pm by W.F. Casey Ebsary, Jr.
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), General Electric Co. v. [read post]